Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 525-534

  Ali, Amna ^a   Sidorova, Tatyana S ^a   Matesic, Diane F ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

Akt kinase; Chaetoglobosin K; JNK; LY294002; Wortmannin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHAETOGLOBOSIN K; NATURAL PRODUCT; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; LUNG CARCINOMA; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; GENES, RAS; HUMANS; INDOLE ALKALOIDS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RATS;

EID: 84879119984     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9883-x     Document Type: Article

References (41)

1. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513-516
2. Jou YS, Layhe B, Matesic DF, Chang CC, de Feijter AW, Lockwood L, et al. (1995) Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene. Carcinogenesis 16:311-317
3. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074
4. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. (2002) Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297:102-104
5. Druker BJ (2002) STI571 (Gleevec™) as a paradigm for cancer therapy. Trends Mol Med 8:S14-S18
6. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M, et al. (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831-3837
7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246
8. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158
9. Ross JS, Schenkein DP, Pietrusko R, Rolfe M, Linette GP, Stec J, et al. (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598-609
10. Xiong HQ (2004) Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol 54:S69-S77
11. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765
12. Flaherty KT, Yasothan U, Kirkpatrick P (2011) Vemurafenib. Nat Rev Drug Discov 10:811-812
13. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, et al. (1997) Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89:457-467
14. Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655-1657
15. Vivanco I, Sawyers CI (2002) The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2:489-501
16. Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF, et al. (1997) Dual role of the phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 277:567-570
17. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, et al. (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394-4399
18. Restuccia DF, Hemmings BA (2009) Blocking Akt-ivity. Science 325:1083-1084
19. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, et al. (2001) AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159:431-437
20. Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV, et al. (2002) Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21:53-64
21. Affara NI, Schanbacher BL, Mihm MJ, Cook AC, Pei P, Mallery SR, et al. (2004) Activated Akt-1 in specific cell populations during multi-stage skin carcinogenesis. Anticancer Res 24:2773-2782
22. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, et al. (2002) Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 8:1168-1171
23. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. (2004) Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 64:5232-5236
24. Antonyak MA, Kenyon LC, Godwin AK, James DC, Emlet DR, Okamoto I, et al. (2002) Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 21:5038-5046
25. Engelberg D (2004) Stress-activated protein kinases - tumor suppressors or tumor initiators? Semin Cancer Biol 14:271-282
26. Khatlani TS, Wislez M, Sun M, Srinivas H, Iwanaga K, Ma L, et al. (2007) c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene 26:2658-2666
27. Cutler HG, Crumley F, Cox R (1980) Chaetoglobosin K: a new plant growth inhibitor and toxin from Diplodia macrospora. J Agric Food Chem 28:139-142
28. Tikoo A, Cutler H, Lo SH, Chen LB, Maruta H (1999) Treatment of Ras-induced cancers by the F-actin cappers Tensin and Chaetoglobosin K, in combination with the Caspase-1 inhibitor N1445. Cancer J Sci Am 5:293-300
29. Matesic DF, Villio KN, Folse SL, Garcia EL, Cutler SJ, Cutler HG (2006) Inhibition of cytokinesis and Akt phosphorylation by chaetoglobosin K in ras-transformed epithelial cells. Cancer Chemother Pharmocol 57:741-754
30. Matesic DF, Blommel ML, Sunman JA, Cutler SJ, Cutler HG (2001) Prevention of organochlorine-induced inhibition of gap junctional communication by chaetoglobosin K in astrocytes. Cell Biol Toxicol 17:395-408
31. Sidorova TS, Matesic DF (2008) Protective effect of the natural product, Chaetoglobosin K, on lindane- and dieldrin-induced changes in astroglia: identification of activated signaling pathways. Pharm Res 25:1297-1308
32. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356
33. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101
34. Kwon T, Kwon DY, Chun J, Kim JH, Kang SS (2000) Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J Biol Chem 275:423-428
35. Murga C, Zohar M, Teramoto H, Gutkind JS (2002) Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappaB. Oncogene 21:207-216
36. Zhang QG, Wang XT, Han D, Yin XH, Zhang GY, Xu TL (2006) Akt inhibits MLK3/JNK3 signaling by inactivating Rac1: a protective mechanism against ischemic brain injury. J Neurochem 98:1886-1898
37. Logan MR, Mandato CA (2006) Regulation of the actin cytoskeleton by PIP2 in cytokinesis. Biol Cell 98:377-388
38. Canman JC, Lewellyn L, Laband K, Smerdon SJ, Desai A, Bowerman B, Oegema K (2008) Inhibition of Rac by the GAP activity of centralspindlin is essential for cytokinesis. Science 322:1543-1546
39. Lim CP, Cao X (1999) Serine phosphorylation and negative regulation of Stat3 by JNK. J Biol Chem 274:31055-31061
40. Rawlings JS, Rosler KM, Harrison DA (2004) The JAK/STAT signaling pathway. J Cell Sci 117:1281-1283
41. Wong MK, Lo AI, Lam B, Lam WK, Ip MS, Ho JC (2010) Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 65:1023-1028